Recurrent or metastatic squamous cell carcinoma of the head and neck research hub

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)

This study looks at new treatments for head and neck cancer that has come back or spread after previous therapies. It compares a new drug, Lenvatinib, alone or with Pembrolizumab, against standard chemotherapy. We want to see if these new approaches help people live longer and improve their health.